ApopLogic Pharma: Cell Death Activators

ApopLogic Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products that target unique apoptotic cell death pathways found in tumor cells and proliferating lymphocytes. The Company was formed in the summer of 2005 to capitalize on the intellectual property of its Scientific Founders, Richard C. Duke and Donald Bellgrau. Drs. Duke and Bellgrau were two of the original founders of GlobeImmune, a biotech company that has successfully raised more than $40 million in financing and grant funding and has grown to more than 50 employees. ApopLogic product candidates and programs include: (1) application of Fas Ligand, a novel apoptotic cell death-inducing molecule with unique pro-inflammatory properties, for the treatment of cancer, hematological malignancies and autoimmune disorders and (2) use of proprietary combinations of cancer chemotherapeutic and T-cell survival factors to treat Sezary leukemia, cutaneous T cell lymphoma and psoriasis. Diseases and conditions targeted by Apoplogic’s products affect large patient populations and cannot be treated satisfactorily with existing therapies.